Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

Summary

The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.

Timeline

Start

2019-10-08

Primary completion

2026-10-19

Completion

2026-10-19

Drugs

Indications